COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended
	Nov. 03, 2015	Jan. 31, 2013	Feb. 28, 2011	Dec. 31, 2008	Mar. 31, 2016	Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Baseline Contractual Rate	20.00%
Notice period for termination of contract prior to start of specified period					90 days
Notice period for termination of contract post start of Phase 3 clinical trials					180 days
Net revenues					$ 1,227	$ 2,785
Phase 3 collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total milestone partially offset	$ 155,000
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received					63,300
Cumulative share of phase 3 collaboration costs					103,300
Milestone payment received		$ 15,000	$ 25,000
Non-Phase 3 tivantinib collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received					79	10
Daiichi Sankyo Tivantinib Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received				$ 60,000
Additional potential development and sales milestone payments				$ 560,000
Milestone payments for official acceptance of drug approval applications	55,000
Milestone payments to be received upon regulatory approvals and first commercial sales	$ 100,000
Net revenues					700	$ 1,400
Deferred revenue					$ 2,100